SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma surges with arm acquiring 11.86% stake in PJSC Biosintez

14 Mar 2019 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 466.15, up by 10.05 points or 2.20% from its previous closing of Rs. 456.10 on the BSE.

The scrip opened at Rs. 463.00 and has touched a high and low of Rs. 468.40 and Rs. 456.30 respectively. So far 720080 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 678.80 on 06-Sep-2018 and a 52 week low of Rs. 375.40 on 18-Jan-2019.

Last one week high and low of the scrip stood at Rs. 475.00 and Rs. 447.75 respectively. The current market cap of the company is Rs. 111425.12 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.53% and 13.09% respectively.

Sun Pharmaceutical Industries’ wholly owned subsidiary -- Sun Pharma (Netherlands) BV has increased its shareholding in PJSC Biosintez, Russia, by way of purchase of 33958 shares equivalent to 11.86% of PJSC Biosintez under Mandatory Tender Offer.

Post the aforesaid purchase, the total holding of Sun Pharma (Netherlands) BV was increased from 85.10% to 96.96% in PJSC Biosintez.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×